From: Diabetic kidney disease in the elderly: prevalence and clinical correlates
< 65 years | 65–75 years | > 75 years | |||||||
---|---|---|---|---|---|---|---|---|---|
eGFR- | eGFR+ | eGFR- | eGFR+ | eGFR- | eGFR+ | ||||
n = 54,297 | n = 3941 | p | n = 44,378 | n = 12,304 | p | n = 23,754 | n = 18,921 | p | |
Male sex | 33,640 (62.0%) | 2301 (58.4%) | < 0.001 | 25,773 (58.1%) | 6696 (54.4%) | < 0.001 | 12,262 (51.6%) | 8618 (45.5%) | < 0.001 |
Age (years) | 56 ± 7 | 60 ± 5 | < 0.001 | 70 ± 3 | 71 ± 3 | < 0.001 | 80 ± 4 | 81 ± 4 | < 0.001 |
Duration of diabetes (years) | 8 ± 7 | 11 ± 9 | < 0.001 | 11 ± 9 | 14 ± 9 | < 0.001 | 14 ± 10 | 16 ± 11 | < 0.001 |
Albuminuria | 13,031 (24.0%) | 1855 (47.1%) | < 0.001 | 11,126 (25.1%) | 5000 (40.6%) | < 0.001 | 6770 (28.5%) | 7605 (40.2%) | < 0.001 |
Retinopathy | 6073 (11.2%) | 925 (23.5%) | < 0.001 | 6208 (14.0%) | 2565 (20.8%) | < 0.001 | 3168 (13.3%) | 3311 (17.5%) | < 0.001 |
BMI (Kg/m2) | 30.3 ± 5.7 | 31.8 ± 6.2 | < 0.001 | 29.3 ± 5.0 | 30.5 ± 5.3 | < 0.001 | 28.0 ± 4.6 | 28.8 ± 4.8 | < 0.001 |
HbA1c (%) | 7.3 ± 1.4 | 7.4 ± 1.5 | < 0.001 | 7.1 ± 1.2 | 7.3 ± 1.3 | < 0.001 | 7.2 ± 1.2 | 7.3 ± 1.3 | < 0.001 |
Triglycerides ≥150 mg/dl | 17,380 (33.8%) | 1916 (52.0%) | < 0.001 | 10,902 (26.1%) | 4792 (42.0%) | < 0.001 | 4696 (21.4%) | 5781 (33.8%) | < 0.001 |
HDL < 40/< 50 mg/dL (Male/Female) | 19,366 (38.3%) | 1837 (51.1%) | < 0.001 | 12,780 (31.1%) | 4939 (44.2%) | < 0.001 | 6188 (28.6%) | 6998 (41.7%) | < 0.001 |
LDL ≥100 mg/dL | 26,449 (52.8%) | 1593 (45.1%) | < 0.001 | 18,723 (45.6%) | 4820 (43.4%) | < 0.001 | 10,034 (46.5%) | 7676 (45.9%) | 0.061 |
Blood Pressure ≥ 140/85 mmHg | 22,307 (47.6%) | 1795 (54.0%) | < 0.001 | 21,453 (56.1%) | 5701 (56.0%) | 0.130 | 11,688 (58.8%) | 8518 (56.6%) | < 0.001 |
Smokers | 8406 (25.5%) | 459 (20.4%) | < 0.001 | 3612 (14.5%) | 823 (12.2%) | < 0.001 | 923 (7.7%) | 570 (6.0%) | < 0.001 |
Cardiovascular therapy | |||||||||
Lipid-lowering treatment | 28,831 (53.1%) | 2571 (65.2%) | < 0.001 | 27,130 (61.1%) | 8360 (67.9%) | < 0.001 | 12,802 (53.9%) | 10,996 (58.1%) | < 0.001 |
Treatment with statins | 25,854 (47.6%) | 2148 (54.5%) | < 0.001 | 25,456 (57.4%) | 7472 (60.7%) | < 0.001 | 12,224 (51.5%) | 10,188 (53.8%) | < 0.001 |
Treatment with fibrates | 1982 (3.7%) | 303 (7.7%) | < 0.001 | 927 (2.1%) | 576 (4.7%) | < 0.001 | 310 (1.3%) | 490 (2.6%) | < 0.001 |
Antihypertensive treatment | 31,773 (58.5%) | 3296 (83.6%) | < 0.001 | 32,412 (73.0%) | 10,619 (86.3%) | < 0.001 | 18,098 (76.2%) | 16,226 (85.8%) | < 0.001 |
Treatment with ACE-Is/ARBs | 27,592 (50.8%) | 2868 (72.8%) | < 0.001 | 27,773 (62.6%) | 9165 (74.5%) | < 0.001 | 14,992 (63.1%) | 13,431 (71.0%) | < 0.001 |
Aspirin | 8470 (15.6%) | 997 (25.3%) | < 0.001 | 10,745 (24.2%) | 3533 (28.7%) | < 0.001 | 6079 (25.6%) | 5460 (28.9%) | < 0.001 |
Antidiabetic therapy | |||||||||
Diet | 3010 (5.5%) | 139 (3.5%) | < 0.001 | 2566 (5.8%) | 520 (4.2%) | < 0.001 | 1262 (5.3%) | 732 (3.9%) | < 0.001 |
Oral antidiabetic drugs | 37,223 (68.6%) | 1927 (48.9%) | < 0.001 | 30,103 (67.8%) | 6276 (51.0%) | < 0.001 | 15,565 (65.5%) | 9441 (49.9%) | < 0.001 |
Oral drugs and insulin | 8685 (16.0%) | 775 (19.7%) | < 0.001 | 7477 (16.8%) | 2429 (19.7%) | < 0.001 | 3878 (16.3%) | 3390 (17.9%) | 0.001 |
Insulin | 5379 (9.9%) | 1100 (27.9%) | < 0.001 | 4232 (9.5%) | 3079 (25.0%) | < 0.001 | 3049 (12.8%) | 5358 (28.3%) | < 0.001 |
Q Score | |||||||||
< 15 | 2345 (4.3%) | 189 (4.8%) | 0.259 | 1353 (3.0%) | 455 (3.7%) | 0.002 | 858 (3.6%) | 735 (3.9%) | 0.262 |
15–25 | 14,230 (26.2%) | 1145 (29.1%) | 0.002 | 10,953 (24.7%) | 3494 (28.4%) | < 0.001 | 6555 (27.6%) | 5788 (30.6%) | < 0.001 |
> 25 | 37,722 (69.5%) | 2607 (66.2%) | < 0.001 | 32,072 (72.3%) | 8355 (67.9%) | < 0.001 | 16,341 (68.8%) | 12,398 (65.5%) | < 0.001 |